| Literature DB >> 29202467 |
Chien-Chia Chen1, Eric Pouliquen2, Alexis Broisat3, Francesco Andreata4, Maud Racapé5, Patrick Bruneval5, Laurence Kessler6,7, Mitra Ahmadi3, Sandrine Bacot3, Carole Saison-Delaplace1,2, Marina Marcaud2, Jean-Paul Duong Van Huyen5, Alexandre Loupy5,8, Jean Villard9, Sandrine Demuylder-Mischler10, Thierry Berney7,10, Emmanuel Morelon1,2,7,11, Meng-Kun Tsai12, Marie-Nathalie Kolopp-Sarda13, Alice Koenig1, Virginie Mathias14, Stéphanie Ducreux14, Catherine Ghezzi3, Valerie Dubois14, Antonino Nicoletti4, Thierry Defrance1, Olivier Thaunat1,2,7,11.
Abstract
Humoral rejection is the most common cause of solid organ transplant failure. Here, we evaluated a cohort of 49 patients who were successfully grafted with allogenic islets and determined that the appearance of donor-specific anti-HLA antibodies (DSAs) did not accelerate the rate of islet graft attrition, suggesting resistance to humoral rejection. Murine DSAs bound to allogeneic targets expressed by islet cells and induced their destruction in vitro; however, passive transfer of the same DSAs did not affect islet graft survival in murine models. Live imaging revealed that DSAs were sequestrated in the circulation of the recipients and failed to reach the endocrine cells of grafted islets. We used murine heart transplantation models to confirm that endothelial cells were the only accessible targets for DSAs, which induced the development of typical microvascular lesions in allogeneic transplants. In contrast, the vasculature of DSA-exposed allogeneic islet grafts was devoid of lesions because sprouting of recipient capillaries reestablished blood flow in grafted islets. Thus, we conclude that endothelial chimerism combined with vascular sequestration of DSAs protects islet grafts from humoral rejection. The reduced immunoglobulin concentrations in the interstitial tissue, confirmed in patients, may have important implications for biotherapies such as vaccines and monoclonal antibodies.Entities:
Keywords: Immunoglobulins; Immunology; Islet cells; Transplantation
Mesh:
Substances:
Year: 2017 PMID: 29202467 PMCID: PMC5749508 DOI: 10.1172/JCI93542
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808